Copyright © 2012 Marzio Pennisi. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. R. A. Morgan, M. E. Dudley, J. R. Wunderlich et al., “Cancer regression in patients after transfer of genetically engineered lymphocytes,” Science, vol. 314, no. 5796, pp. 126–129, 2006. View at Publisher · View at Google Scholar · View at Scopus
2. S. A. Rosenberg, N. P. Restifo, J. C. Yang, R. A. Morgan, and M. E. Dudley, “Adoptive cell transfer: a clinical path to effective cancer immunotherapy,” Nature Reviews Cancer, vol. 8, no. 4, pp. 299–308, 2008. View at Publisher · View at Google Scholar · View at Scopus
3. I. Melero, I. Martinez-Forero, J. Dubrot, N. Suarez, A. Palazón, and L. Chen, “Palettes of vaccines and immunostimulatory monoclonal antibodies for combination,” Clinical Cancer Research, vol. 15, no. 5, pp. 1507–1509, 2009. View at Publisher · View at Google Scholar · View at Scopus
4. J. L. Perez-Gracia, P. Berraondo, I. Martinez-Forero et al., “Clinical development of combination strategies in immunotherapy: are we ready for more than one investigational product in an early clinical trial?” Immunotherapy, vol. 1, no. 5, pp. 845–853, 2009. View at Publisher · View at Google Scholar · View at Scopus
5. I. Tirapui, A. Arina, G. Mazzolinii et al., “Improving efficacy of interleukin-12-transfected dendritic cells injected into murine colon cancer with anti-CD137 monoclonal antibodies and alloantigens,” International Journal of Cancer, vol. 110, no. 1, pp. 51–60, 2004. View at Publisher · View at Google Scholar · View at Scopus
6. I. Tirapu, E. Huarte, C. Guiducci et al., “Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma,” Cancer Research, vol. 66, no. 4, pp. 2442–2450, 2006. View at Publisher · View at Google Scholar · View at Scopus
7. A. Palazón, A. Teijeira, I. Martínez-Forero et al., “Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes,” Cancer Research, vol. 71, no. 3, pp. 801–811, 2011. View at Publisher · View at Google Scholar · View at Scopus
8. I. Melero, O. Murillo, J. Dubrot, S. Hervás-Stubbs, and J. L. Perez-Gracia, “Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies,” Trends in Pharmacological Sciences, vol. 29, no. 8, pp. 383–390, 2008. View at Publisher · View at Google Scholar · View at Scopus
9. J. Dubrot, F. Milheiro, C. Alfaro et al., “Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ,” Cancer Immunology, Immunotherapy, vol. 59, no. 8, pp. 1223–1233, 2010. View at Publisher · View at Google Scholar · View at Scopus
10. I. Melero, S. Hervas-Stubbs, M. Glennie, D. M. Pardoll, and L. Chen, “Immunostimulatory monoclonal antibodies for cancer therapy,” Nature Reviews Cancer, vol. 7, no. 2, pp. 95–106, 2007. View at Publisher · View at Google Scholar · View at Scopus
11. F. Ito, Q. Li, A. B. Shreiner et al., “Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines,” Cancer Research, vol. 64, no. 22, pp. 8411–8419, 2004. View at Publisher · View at Google Scholar · View at Scopus
12. K. F. May Jr., L. Chen, P. Zheng, and Y. Liu, “Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8⁺ T cells,” Cancer Research, vol. 62, no. 12, pp. 3459–3465, 2002. View at Scopus
13. F. Pappalardo, I. M. Forero, M. Pennisi, A. Palazon, I. Melero, and S. Motta, “SimB16: modeling induced immune system response against B16-melanoma,” PLoS ONE, vol. 6, no. 10, Article ID e26523. View at Publisher · View at Google Scholar
14. A. K. Laird, “Dynamics of tumor growth,” British Journal of Cancer, vol. 13, pp. 490–502, 1964. View at Scopus
15. J. M. Mitchison, The Biology of the Cell Cycle, Cambridge University Press, 1971.
16. W. H. Clark, A. M. Ainsworth, E. A. Bernardino, C. H. Yang, C. M. Mihm, and R. J. Reed, “The developmental biology of primary human malignant melanomas,” Seminars in Oncology, vol. 2, no. 2, pp. 83–103, 1975. View at Scopus
17. M. Pennisi, F. Pappalardo, and S. Motta, “Agent based modeling of lung metastasis-immune system competition,” Lecture Notes in Computer Science, vol. 5666, pp. 1–3, 2009. View at Publisher · View at Google Scholar · View at Scopus
18. M. Pennisi, F. Pappalardo, A. Palladini et al., “Modeling the competition between lung metastases and the immune system using agents,” BMC Bioinformatics, vol. 11, supplement 7, article S13, 2010. View at Publisher · View at Google Scholar · View at Scopus
19. Y. Lotan and C. G. Roehrborn, “Clearance rates of total prostate specific antigen (PSA) after radical prostatectomy in African-Americans and Caucasians,” Prostate Cancer and Prostatic Diseases, vol. 5, no. 2, pp. 111–114, 2002. View at Publisher · View at Google Scholar · View at Scopus
20. D. Pardoll, “T cells take aim at cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 25, pp. 15840–15842, 2002. View at Publisher · View at Google Scholar · View at Scopus
21. J. V. Peppard and E. Orlans, “The biological half-lives of four rat immunoglobulin isotypes,” Immunology, vol. 40, no. 4, pp. 683–686, 1980. View at Scopus
22. H. Narazaki, Y. Zhu, L. Luo, G. Zhu, and L. Chen, “CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells,” Blood, vol. 115, no. 10, pp. 1941–1948, 2010. View at Publisher · View at Google Scholar · View at Scopus
23. S. Marino, I. B. Hogue, C. J. Ray, and D. E. Kirschner, “A methodology for performing global uncertainty and sensitivity analysis in systems biology,” Journal of Theoretical Biology, vol. 254, no. 1, pp. 178–196, 2008. View at Publisher · View at Google Scholar · View at Scopus